Trial Profile
A phase III randomised, double-blind, active-controlled parallel group efficacy and safety study of BI 10773 compared to glimepiride administered orally during 104 weeks with a 104-week extension period in patients with type 2 diabetes mellitus and insufficient glycaemic control despite metformin treatment
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Jan 2022
Price :
$35
*
At a glance
- Drugs Empagliflozin (Primary) ; Glimepiride
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms C-SCADE-7; EMPA-REG H2H-SU
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 31 Jul 2018 Results of pooled analysis (see profiles: 56615, 57731, 58105, 58520 and 60013) investigating the effect of empagliflozin on aminotransferases published in the Diabetologia
- 16 Sep 2016 Results of a pooled analysis assessing risk of bone fracture presented at the 52nd Annual Meeting of the European Association for the Study of Diabetes
- 16 Sep 2016 Results assessing safety data from 18 trials presented at the 52nd Annual Meeting of the European Association for the Study of Diabetes